Utama › Mieloma Pelbagai › New Mexico
Kajian klinikal Mieloma Pelbagai di New Mexico
5 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi di New Mexico.
Teks kajian rasmi (Bahasa Inggeris)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Christus St. Vincent Regional Cancer Center, Santa Fe
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07518186A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Christus St. Vincent Regional Cancer Center, Santa Fe
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05552222TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- The University of New Mexico Comprehensive Cancer Center, Albuquerque
- dan 2 lagi
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Farmington
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT07227311Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- dan 1 lagi
Mengambil pesertaFasa 3
Semua umur · Semua jantina · Dikemas kini 10 Jun 2026 · NCT05561387Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.